Takeda's QDENGA has become the first dengue vaccine approved in India, a country that accounts for nearly one-third of the global dengue burden. The approval is critical as India's dengue cases have risen 11-fold in two decades. Takeda will partner with Biological E to produce 50 million doses annually. The vaccine protects against all four serotypes without requiring prior exposure or testing.
QDENGA regulatory approval
- ▪QDENGA is the first dengue vaccine to be approved in India
- ▪Takeda Pharmaceutical's dengue vaccine, QDENGA, has been approved by India's drug regulator
Vaccine characteristics
- ▪The QDENGA vaccine can be administered regardless of prior dengue exposure and does not require pre-vaccination testing
- ▪QDENGA is a tetravalent live-attenuated vaccine designed to protect against all four dengue virus serotypes
- ▪Long-term data for QDENGA demonstrated sustained protection against dengue disease and dengue-related hospitalization
Dengue burden in India
- ▪India accounts for nearly one-third of the global dengue burden
- ▪Reported dengue cases in India have increased 11-fold in the past two decades
Manufacturing partnership
- ▪Takeda partnered with Indian vaccine maker Biological E in 2024 to expand manufacturing of QDENGA
- ▪Indian vaccine maker Biological E plans to build capacity to produce 50 million doses of QDENGA annually
- ▪Takeda aims to manufacture 100 million doses of QDENGA a year globally by the end of the decade
Global distribution
- ▪More than 32 million doses of QDENGA have been distributed globally since the vaccine's launch
- ▪Since its launch in 2022, QDENGA has been approved in 43 countries
Story comments
Loading comments…